Drug Shortage Report for FUROSEMIDE INJ USP
Report ID | 125153 |
Drug Identification Number | 00527033 |
Brand name | FUROSEMIDE INJ USP |
Common or Proper name | FUROSEMIDE INJ USP |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | FUROSEMIDE |
Strength(s) | 10MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
Packaging size | 4ML 10 LIVI CA |
ATC code | C03CA |
ATC description | HIGH-CEILING DIURETICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-09-25 |
Estimated end date | 2021-01-15 |
Actual end date | 2021-01-18 |
Shortage status | Resolved |
Updated date | 2021-01-19 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-09-28 | English | Compare |
v2 | 2020-09-28 | French | Compare |
v3 | 2021-01-19 | English | Compare |
v4 | 2021-01-19 | French | Compare |
Showing 1 to 4 of 4